胃癌病人ERCC1和XPD基因多态性与奥沙利铂化疗预后关系

目的了解DNA损伤修复基因ERCC1 Asn118Asn和XPD Lys751Gln多态性与接受以奥沙利铂为基础化疗的晚期胃癌病人预后的关系。方法 90例晚期胃癌病人接受奥沙利铂化疗前抽取静脉血并提取DNA,应用real-ti me PCR法进行基因分型。比较病人不同基因型与生存期的关系。结果晚期胃癌病人ERCC1Asn118Asn基因型频率为C/C 47.78%,C/T42.22%,T/T10.00%;XPD基因型频率分别为A/A80.00%,A/C16.67%,C/C 3.33%。90例胃癌病人中位无疾病进展生存期（TTP）6.4个月,总生存期（OS）9.5个月。ERCC1C/C基因型病人中位TTP为6.6个月,OS为9.7个月;C/T＋T/T型病人中位TTP为6.1个月,OS为9.1个月,二者差异无统计学意义（P〉0.05）。XPD A/A基因型病人中位TTP为6.7个月,OS为9.7个月;A/C＋C/C基因型病人中位TTP为4.8个月,OS为7.8个月,二者差异有统计学意义（χ2=20.244、17.113,P〈0.05）。同时携带ERCC1 C/C及XPD A/A基因型、ERCC1 C/C及XPD A/C＋C/C基因型、ERCC1 C/T＋T/T及XPD A/A基因型、ERCC1 C/T＋T/T及XPD A/C＋C/C基因型的病人中位TTP分别为6.9、4.7、6.3和5.0个月,OS为9.9、7.7、9.3、8.0个月,4组差异有统计学意义（χ2=18.331、12.742,P〈0.05）。结论 XPD Lys751Gln基因多态性与以接受奥沙利铂为基础化疗的晚期胃癌病人的生存期有关,ERCC1 Asn118Asn基因多态性与接受奥沙利铂为基础化疗的晚期胃癌病人的生存期无关。     

血红蛋白水平对晚期胃癌患者化疗疗效及预后的影响

目的 探讨化疗前血红蛋白（Hb）水平对晚期胃癌患者化疗疗效及预后的影响.方法 选择2008年1月～2012年1月期间新乐市社会保险职工医院收治的86例晚期胃癌患者作为研究对象,所有患者均接受SOX化疗方案至少2个周期,化疗前及化疗2个周期后测定Hb值,比较化疗前不同年龄、性别、ECOG评分、肿瘤分化程度、不同位置肿瘤患者Hb值,并比较86例患者化疗前后的Hb值、有效和无效患者化疗前Hb值及贫血患者和非贫血患者的化疗有效率,对患者随访观察,比较贫血患者和非贫血患者生存时间.结果 化疗前不同年龄、性别、ECOG评分、肿瘤分化程度、不同位置肿瘤患者Hb含量差异均无统计学意义（t/F值=0.568～0.904,P值均＞o.05）,发生内脏转移、腹腔转移患者Hb值分别高于无内脏转移、无腹腔转移患者[（116.9±19.5）g/L vs （107.2±18.7）g/L,（116.5±18.6）g/L vs （106.1±19.8）g/L;t=2.301,2.221,P=0.024,o.029];化疗前86例患者Hb值高于化疗后[（111.3±18.6）g/L vs （104.5±17.8）g/L,t=2.449,P=o.015];所有患者中化疗后有效36例,无效50例,有效患者化疗前Hb值高于无效患者[（115.8±18.7）g/L vs（106.3±17.4）g/L;t=2.421,P=0.018];化疗前58例患者贫血,28例患者不存在贫血,化疗前非贫血患者有效率高于贫血患者（57.1％ vs 34.5％,Z=3.984,P=0.046）,平均生存时间稍长于贫血患者[（463.6±156.4）天vs （397.1±149.8）天,t=1.902,P=0.061）].结论 晚期胃癌患者Hb含量降低,伴有贫血患者化疗疗效及预后较差.     

XRCC1、XPD单核苷酸多态性与肺癌铂类化疗的临床预后研究

目的DNA修复基因XRCC1和XPD是参与铂-DNA加合物修复中的关键因子。探讨肿瘤石蜡组织中XR-（321、XPD单核苷酸多态性与接受铂类药物化疗非小细胞肺癌（NSCLC）患者临床预后之间的关系。方法采用TaqMan探针Real-time PCR方法评价53例石蜡包埋NSCLC组织中DNA修复基因XRCC1第399位密码子、XPD第751位密码子的多态性，并比较不同基因型与NSCLC肿瘤组织临床病理及铂类化疗预后之间的关系。结果XRCC1 Arg399Gin、XPD Lys751Gln基因多态性与NSCLC患者临床及肿瘤病理特征均未见相关性。携带XRC1 Arg／Arg或Arg／Gln基因型NSCLC患者经铂类化疗后的平均总生存时间为24．0月，而携带Gln／Gln基因型患者仅为8．0月，两者有统计学差异（P=0．02）。XPD Lys751Gln与NSCLC患者无进展生存期和总生存时闯均未见显著性差异（P〉0．05）。XPD和XROC1的多态性联合分析显示变异型等位基因的个数增加与总生存时间（P=0．015）相关。Cox比例风险模型显示XRCC1 Arg399Gln可以独立预测NSCLC患者的总生存时间（P=0．011）。结论XRCC1 Arg399Gln、XPD Lys751Gln基因多态性与NSCLC肿瘤临床病理特征无关。XRCC1 Arg399GIn基因多态性与NSCLC患者的总生存时间有关，在一定程度上可以作为判断NSCLC患者铂类药物化疗的预后指标。XRCC1和XPD SNP在铂类药物化疗预后方面可能存在一定的联合作用。     

XRCC1、XPD单核苷酸多态性与肺癌铂类化疗的临床预后研究

目的DNA修复基因XRCC1和XPD是参与铂-DNA加合物修复中的关键因子。探讨肿瘤石蜡组织中XR- CC1、XPD单核苷酸多态性与接受铂类药物化疗非小细胞肺癌(NSCLC)患者临床预后之间的关系。方法采用TaqMan探针Real-time PER方法评价53例石蜡包埋NSCLC组织中DNA修复基因XRCC1第399位密码子、XPD第751位密码子的多态性,并比较不同基因型与NSCLC肿瘤组织临床病理及铂类化疗预后之间的关系。结果XRCC1 Arg399Gln、XPD Lys751Gln基因多态性与NSCLC患者临床及肿瘤病理特征均未见相关性。携带XRCC1 Arg/Arg或Arg/Gln基因型NSCLC患者经铂类化疗后的平均总生存时间为24.0月,而携带Gln/Gln基因型患者仅为8.0月,两者有统计学差异(P=0.02)。XPD Lys751Gln与NSCLC患者无进展生存期和总生存时间均未见显著性差异(P>0.05)。XPD和XRCC1的多态性联合分析显示变异型等位基因的个数增加与总生存时间(P=0.015)相关。Cox比例风险模型显示XRCC1 Arg399Gln可以独立预测NSCLC患者的总生存时间(P=0.011)。结论XRCC1 Arg399Gln、XPD Lys751Gln基因多态性与NSCLC肿瘤临床病理特征无关。XRCC1 Arg399Gln基因多态性与NSCLC患者的总生存时间有关,在一定程度上可以作为判断NSCLC患者铂类药物化疗的预后指标。XRCC1和XPD SNP在铂类药物化疗预后方面可能存在一定的联合作用。     

GSTA1基因多态性对环磷酰胺辅助化疗的乳腺癌患者预后的影响

目的 探讨GSTA1基因多态性与接受CTX类药物辅助化疗乳腺癌患者预后的关系.方法 对采用CTX类药物为主的方案进行辅助化疗的137例确诊乳腺癌患者(浸润性导管癌患者124例,浸润性小叶癌患者5例,其他类型癌症患者8例),用PCR-LDR检测其GSTA1基因多态性,Kaplan-Meier法绘制生存曲线,log-rank法比较不同基因型组间生存差异,并用Cox比例风险回归模型进行预后影响因素的多因素分析.结果 137例乳腺癌患者中,GSTA1*A/*A、*A/*B和-B/*B基因型频率分别为67.2%(92/137)、31.4%(43/137)和1.5%(2/137).乳腺癌患者的GSTA1基因型频率在按年龄、临床分期、淋巴结转移、雌、孕激素受体状态等临床病理特征分组的分布差异均无统计学意义(x2值分别为0.722、1.967、3.303、0.226、0.709,P均＞0.05);经Fisher精确概率分析,肿瘤大小、病理组织类型、病理分级的差异均无统计学意义(P均＞0.05).携带GSTA1-A/*A基因型和*A/*B或*B/-B基因型的乳腺癌患者复发率分别为47.8%(44/92)和31.1%(14/45),死亡率分别为22.8%(21/92)和17.8%(8/45).Kaplan-Meier生存曲线和log-rank分析显示,携带GSTA1*A/*B+*B/*B基因型乳腺癌患者的无复发生存率和总生存率均高于携带GSTA1*A/*A基因型患者,且差异均有统计学意义(x2值分别为18.723、7.352,P均＜0.01).经Cox多因素分析,GSTA1基因多态性是影响乳腺癌患者无复发生存[OR=0.222,95%CI:0.108～0.458,P＜0.01]和总生存[OR=0.362,95%CI:0.145～0.902,P＜0.05]的独立因素.结论 GSTA1基因多态性是乳腺癌患者CTX药物辅助化疗无复发生存和总生存的预测标志.

Abstract：

Objective To investigate the association between the genetic polymorphisms in GSTA1 and the clinical outcome of breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy. Methods A total of 137 breast cancer patients receiving cyclophosphamide-based adjuvant chemotherapy were recruited ( 124 cases with infiltrative ductal carcinoma, 5 cases with infiltrative lobular carcinoma and 8 cases with other histological types). PCR-LDR method was used to detect the genotypes of GSTA1. Survival curves were generated by the Kaplan-Meier method, and verified by the log-rank test. Cox proportional hazards regression analysis was used to estimate the prognostic factors in multivariate analysis. Results Of the 137 breast cancer patients, the genotypic frequencies of the GSTA1 * A/* A,* A/* B and * B/* B were 67.2% ( 92/137 ), 31.4% ( 43/137 ) and 1.5% ( 2/137 ), respectively. No significant differences were found between the genotypic frequencies and groups categorization according to age, stage, lymph node metastasis, ER or PR status (x2 = 0. 722,1. 967, 3. 303, 0. 226 and 0. 709, all P ＞0. 05 ) ;through Fisher exact test, also no significant differences were found between the genotypic frequencies and group categorization according to tumor size, histological types and grading ( all P ＞ 0. 05 ) . The recurrence rates in patients with GSTA1 * A/* A and * A/* B or * B/* B genotypes were 47. 8% (44/92) and 31.1% ( 14/45 ), respectively, and the mortality rates were 22. 8% ( 21/92 ) and 17. 8% ( 8/45 ),respectively. Patients with GSTA1 * A/* B and * B/* B genotypes were significantly associated with reduced hazard of relapse (x2 =18.723, P＜0. 01)and mortality (x2 =7.352, P＜0.01), compared to cases with the common * A/* A genotypes, according to Kaplan-Meier survival analysis and log-rank test. Moreover,Cox multivariate analysis showed that GSTA1 polymorphisms appeared to be an independent risk factor for recurrence-free survival ( OR =0. 222, 95% CI:0. 108-0. 458, P ＜0. 01 ) and overall survival ( OR =0. 362,95% CI:0. 145-0. 902, P ＜ 0. 05 ). Conclusion These data indicate that GSTA1 polymorphism may be a potential prognostic factor for recurrence-free survival and overall survival in breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy.     

奥沙利铂为主联合其他药物化疗治疗晚期胃癌的临床疗效及护理

目的探讨以奥沙利铂为主联合其他药物化疗治疗晚期胃癌的临床效果及应用价值，并提出相应的护理干预措施。方法回顾性分析300例晚期胃癌患者的临床资料，临床治疗采用以奥沙利铂加入葡萄糖注射液静脉滴注为主联合亚叶酸钙静脉滴注及5．氟尿嘧啶静脉持续泵入化疗，并针对患者的病情发展及预后，提出综合、全面、精心的护理干预措施。观察患者治疗期间出现的不良反应及治疗效果，并比较护理前后患者及家属对护理工作质量满意度的评分。结果所有患者完成化疗后，临床治疗效果总有效为177例，总有效率为59．0％；化疗期间出现16例不良反应，发生率为513％；实施护理干预前，患者及家属对护理工作质量的满意度评分为（82．3~1．4）分，护理干预后，患者及家属对护理工作质量的满意度评分为（97．3~2．5）分，二者比较，护理干预后患者及家属对护理工作质量的评分明显高于护理干预前。结论临床采用以奥沙利铂为主联合亚叶酸钙及5-氟尿嘧啶化疗治疗晚期胃癌的临床效果较好，不良反应较小，并配合综合、全面、精心的护理干预措施，从患者的心理、生理、饮食等方面进行调节，能够改善患者的预后，值得临床进一步推广应用。     

LTA单核苷酸多态性与胃癌易感性关系的研究进展

尽管世界范围内胃癌的发病率和死亡率有下降趋势,但是近年来我国胃癌发病率和死亡率仍在逐渐上升,已经成为影响人们生存质量的主要因素之一。胃癌的发病机制与多种因素有关,涉及基因多态性、炎性细胞因子及生化机制等,其中淋巴毒素-α(LTA)基因单核苷酸多态性成为近年来研究胃癌致病机理的热点之一。目前发现LTA rs909253(A/G)、rs1041981(C/A)、rs2229094(T/C)、rs746868(G/C)等与胃癌患病风险有一定关联,但尚未得出一致性的结论。本文就目前LTA基因多态性与胃癌易感性的研究进展进行综述。     

GSTA1基因多态性对环磷酰胺辅助化疗的乳腺癌患者预后的影响

Objective To investigate the association between the genetic polymorphisms in GSTA1 and the clinical outcome of breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy. Methods A total of 137 breast cancer patients receiving cyclophosphamide-based adjuvant chemotherapy were recruited ( 124 cases with infiltrative ductal carcinoma, 5 cases with infiltrative lobular carcinoma and 8 cases with other histological types). PCR-LDR method was used to detect the genotypes of GSTA1. Survival curves were generated by the Kaplan-Meier method, and verified by the log-rank test. Cox proportional hazards regression analysis was used to estimate the prognostic factors in multivariate analysis. Results Of the 137 breast cancer patients, the genotypic frequencies of the GSTA1 * A/* A,* A/* B and * B/* B were 67.2% ( 92/137 ), 31.4% ( 43/137 ) and 1.5% ( 2/137 ), respectively. No significant differences were found between the genotypic frequencies and groups categorization according to age, stage, lymph node metastasis, ER or PR status (x2 = 0. 722,1. 967, 3. 303, 0. 226 and 0. 709, all P ＞0. 05 ) ;through Fisher exact test, also no significant differences were found between the genotypic frequencies and group categorization according to tumor size, histological types and grading ( all P ＞ 0. 05 ) . The recurrence rates in patients with GSTA1 * A/* A and * A/* B or * B/* B genotypes were 47. 8% (44/92) and 31.1% ( 14/45 ), respectively, and the mortality rates were 22. 8% ( 21/92 ) and 17. 8% ( 8/45 ),respectively. Patients with GSTA1 * A/* B and * B/* B genotypes were significantly associated with reduced hazard of relapse (x2 =18.723, P＜0. 01)and mortality (x2 =7.352, P＜0.01), compared to cases with the common * A/* A genotypes, according to Kaplan-Meier survival analysis and log-rank test. Moreover,Cox multivariate analysis showed that GSTA1 polymorphisms appeared to be an independent risk factor for recurrence-free survival ( OR =0. 222, 95% CI:0. 108-0. 458, P ＜0. 01 ) and overall survival ( OR =0. 362,95% CI:0. 145-0. 902, P ＜ 0. 05 ). Conclusion These data indicate that GSTA1 polymorphism may be a potential prognostic factor for recurrence-free survival and overall survival in breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy.     

GSTA1基因多态性对环磷酰胺辅助化疗的乳腺癌患者预后的影响

Objective To investigate the association between the genetic polymorphisms in GSTA1 and the clinical outcome of breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy. Methods A total of 137 breast cancer patients receiving cyclophosphamide-based adjuvant chemotherapy were recruited ( 124 cases with infiltrative ductal carcinoma, 5 cases with infiltrative lobular carcinoma and 8 cases with other histological types). PCR-LDR method was used to detect the genotypes of GSTA1. Survival curves were generated by the Kaplan-Meier method, and verified by the log-rank test. Cox proportional hazards regression analysis was used to estimate the prognostic factors in multivariate analysis. Results Of the 137 breast cancer patients, the genotypic frequencies of the GSTA1 * A/* A,* A/* B and * B/* B were 67.2% ( 92/137 ), 31.4% ( 43/137 ) and 1.5% ( 2/137 ), respectively. No significant differences were found between the genotypic frequencies and groups categorization according to age, stage, lymph node metastasis, ER or PR status (x2 = 0. 722,1. 967, 3. 303, 0. 226 and 0. 709, all P ＞0. 05 ) ;through Fisher exact test, also no significant differences were found between the genotypic frequencies and group categorization according to tumor size, histological types and grading ( all P ＞ 0. 05 ) . The recurrence rates in patients with GSTA1 * A/* A and * A/* B or * B/* B genotypes were 47. 8% (44/92) and 31.1% ( 14/45 ), respectively, and the mortality rates were 22. 8% ( 21/92 ) and 17. 8% ( 8/45 ),respectively. Patients with GSTA1 * A/* B and * B/* B genotypes were significantly associated with reduced hazard of relapse (x2 =18.723, P＜0. 01)and mortality (x2 =7.352, P＜0.01), compared to cases with the common * A/* A genotypes, according to Kaplan-Meier survival analysis and log-rank test. Moreover,Cox multivariate analysis showed that GSTA1 polymorphisms appeared to be an independent risk factor for recurrence-free survival ( OR =0. 222, 95% CI:0. 108-0. 458, P ＜0. 01 ) and overall survival ( OR =0. 362,95% CI:0. 145-0. 902, P ＜ 0. 05 ). Conclusion These data indicate that GSTA1 polymorphism may be a potential prognostic factor for recurrence-free survival and overall survival in breast cancer patients treated with cyclophosphamide-based adjuvant chemotherapy.     

晚期胃癌XPG及GSTP1基因多态性与奥沙利铂化疗效果的关系

目的探讨人着色性干皮病G组（XPG）及谷胱甘肽巯基转移酶P1（GSTP1）基因多态性与晚期胃癌以奥沙利铂为主的化疗敏感性的关系。方法 80例Ⅳ期胃癌病人化疗前采集外周静脉血,提取DNA,用实时荧光PCR技术检测XPG C46T及GSTP1 A105G基因的单核苷酸多态性（SNP）分型,比较不同基因型与化疗效果的关系。结果 80例病人XPG C46T基因C/C与T/T＋C/T及GSTP1 A105G基因A/A与A/G＋G/G基因型化疗有效率比较差异均有显著意义（χ^2=5.459、5.291,P〈0.05）。同时携带XPG C46T C/C和GSTP1 A105G A/G＋G/G基因型病人化疗敏感性是同时携带XPG C46T C/T＋T/T和GSTP1 A105G A/A基因型病人的4.886倍（OR=4.886,P〈0.05）。结论 XPG C46T、GSTP1 A105G基因多态性可能与晚期胃癌病人接受以奥沙利铂为主一线化疗药物化疗后的效果有关。     

IL-1B基因-31位点基因多态性与胃癌的关系

目的研究白介素1B(interleukin-1B,IL-1B)基因启动子区-31位点基因多态性在正常人群和胃癌患者中的分布,分析IL-1B-31基因多态性分布是否与性别有关,探讨IL-1B-31基因多态性与胃癌发生的关系。方法收集101例胃癌患者和113名正常健康人外周血标本,提取DNA,用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法检测IL-1B启动子区-31位点基因多态性(C→T)。结果IL-1B基因-31位点基因多态性在正常人群和胃癌患者中的分布无显著性差异,与性别无关,携带-31C等位基因可增加患胃癌的危险性。结论IL-1B-31位点基因多态性可能与胃癌的发生无关。     

LTA基因单核苷酸多态位点与胃癌易感性的研究

目的通过对江西地区汉族胃癌患者和正常人群中淋巴毒素-α（LTA）基因单核苷酸多态（single nucleotide polymorphism,SNP）位点rs909253基因型的检测,探讨rs909253位点与胃癌患者易感性的关系。方法利用Sequenom-MassArray-IPLEX检测194例胃癌和250例对照LTA基因多态位点rs909253的基因分型,并利用非条件logistic回归对检测结果进行相关统计。结果 LTA rs909253多态位点GG、GA、AA三种基因型在胃癌的频率分别为26.4%、52.0%和21.6%,与对照组（35.6%、46.4%和18.0%）相比,统计学上无显著意义（χ2=4.403,P=0.111）;但胃癌组和正常组的等位基因频率分布差异临近显著,P值达0.059;对年龄和性别进行校正后,携带等位基因G的胃癌发病风险有所增加（OR=1.315,95%CI：1.001~1.728）。结论江西汉族人群胃癌的遗传易感性可能与LTA基因rs909253位点的单核苷酸多态性有关,G等位基因为其发病的危险因素。     

MassARRAY Assay高通量技术检测胃癌LTA单核苷酸多态性及其临床应用

目的探讨LTA基因单核苷酸多态性与胃癌易感性的相关性。方法选择60例胃癌患者和60例健康人群为研究对象。采用Mass ARRAY Assay高通量技术检测淋巴毒素-α(LTA)基因单核苷酸(SNP)位点rs909253基因多态性,分析其出现频率及与胃癌易感性的相关性。结果胃癌组与正常组在AA基因频率(20.00%vs.21.67%)差异无统计学意义;G等位基因、GA、GG+GA基因型或变异基因型与胃癌易感风险相关[OR(95%CI):1.48(1.15~1.99)、1.36(1.05~1.68、1.32(1.22~1.65)]。结论 LTA基因rs909253位点单核苷酸多态性与胃癌易感性相关,G等位基因、GG、GA、GG+GA基因型或变异基因型可能是胃癌发病的危险因素。     

单核苷酸多态性与胃癌易感性的相关性

目的 探讨单核苷酸多态性与胃癌易感性的相关性.方法 应用基因测序仪对120例胃癌患者与112例健康对照者的血样EZH2rs734004、r734005、rs2072407、rs6464926及rs12670401多态性进行测序,再应用组织芯片技术与免疫组化检测80例同一来源胃癌组织与24例癌旁正常胃黏膜组织EZH2蛋白的表达情况.结果 rs12670401最小等位基因C与rs6464926最小等位基因T增加,其胃癌发生风险较大(OR＞1),而其余三种多态性则会降低胃癌发生风险.经Codominant模型、Dominant模型及Recessive模型分析,rs12670401CC与rs6464926TT构成比显著高于对照组,可增加胃癌的发生风险(OR＞1),胃癌患者中杂合基因rs2072407TC、rs734005TC及rs734004CG构成比均显著低于对照组,可降低胃癌的发生风险(OR＜1).结论 EZH2基因单核苷酸多态性与胃癌易感性存在较为紧密的关系,且不同SNP等位基因对胃癌发生具有不同影响.     

Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection

Gastric cancer (GC) has a high morbidity worldwide each year especially in China and advanced GC is well known with poor prognosis, for which surgical resection combine adjuvant chemotherapy is the optimal choice for therapy. Leukocyte is an important index during the treatment for its influence on drugs’ dosage and tolerance. Therefore, peripheral blood leukocyte and its subsets during adjuvant chemotherapy may have great clinical value for predicting prognostic. In this retrospective study, we showed the distribution of white blood cell and its subsets in the baseline period before adjuvant chemotherapy in 399 patients who underwent radical resection for advanced GC from January 1, 2008 to August 31, 2012. We investigated the relationship between leukocyte count and overall survival (OS) as well as disease-free survival (DFS). In these patients, females were more likely to have less white blood cells after operation (P = 0.016). Patients with pre-chemotherapy leukocyte count less than 4 × 10⁹/L got worse DFS (P = 0.028) and OS (P = 0.016). In multivariate analysis, tumor size ≥ 6 cm (P = 0.033), TNM stage IV (P = 0.024), vascular or nerval invasion (P = 0.005) and leukocyte count less than 4.0 × 10⁹/L (P = 0.019) was associated with poor DFS. TNM stage IV (P = 0.008), vascular or nerval invasion (P = 0.001) and lower leukocyte count (P = 0.045) were independent risk factors for poor OS. Taken together, our findings suggest that pre-adjuvant chemotherapy peripheral blood leukocyte count correlates with clinical outcome of patients with advanced GC after radical resection.     

单核细胞趋化蛋白-1基因A-2518G多态性与急性冠脉综合征相关性研究

目的 探讨中国苏南地区汉族人群单核细胞趋化蛋白-1(MCP-1)基因启动子区A-2518G单核苷酸多态性与ACS发病的相关性.方法 采用病例-对照研究方法,选择临床确诊的ACS 484例(ACS组),其中急性心肌梗死(AMI) 290例,不稳定性心绞痛(UAP) 194例.经冠脉造影排除冠心病者346例为对照组,包括冠脉硬化症(CAS组)166例和冠脉无狭窄(冠脉正常组)180例.利用聚合酶链式反应-限制性酶切片段长度多态性技术(PCR-RFLP)检测MCP-1基因A-2518G多态性.结果 MCP-1基因A-2518G单核苷酸多态性在ACS组和对照组中均存在AA、AG和GG三种基因型.二组基因型分布符合Hardy- Weinberg平衡(P＞0.05),具有群体代表性.与对照组相比,ACS组中AA (15.32％vs.16.12％)、AG (53.47％ vs.51.86％)和GG(31.21％vs.32.02％)基因型和G(57.95％ vs.57.95％)等位基因频率差异均无统计学意义(P值分别为0.083、0.673、0.821和1.000).对性别、年龄、吸烟、糖尿病、TC和LDL等6个相关因素行Logistic回归分析显示,MCP-1基因A-2518G单核苷酸多态性与ACS的发病无相关性(P＞0.05).对男性ACS、女性ACS、AMI、UAP和早发ACS等5个亚组进行MCP-1基因A-2518G多态性分析,结果显示,男性和女性ACS分别与对照组相比、AMI和UAP分别与冠脉正常组相比以及早发ACS与年龄相匹配的对照组相比,AA、AG和GG基因型和G等位基因频率差异均无统计学意义(均P＞0.05).结论 在中国苏南地区汉族人群中,MCP-1基因存在A-2518G单核苷酸多态性,该多态性与ACS发病无显著相关性.     

内蒙古地区炭疽芽胞杆菌基因单核苷酸多态性研究

目的研究内蒙古地区炭疽芽胞杆菌基因单核苷酸多态性(SNP)特征。方法选择内蒙古地区不同分离年代、地点和来源的22株炭疽芽胞杆菌,采用实时荧光定量聚合酶链反应(real-time PCR)方法扩增染色体上的13个SNP位点,进行聚类分析。结果使用的13个SNP位点中8个位点相同,5个位点存在多态性。通过聚类分析,22株炭疽芽胞杆菌可分为4个群,属于A.Br.Aust94亚群和A.Br.008/009亚群的菌株各有1株,A.Br.Ames亚群和A.Br.001/002亚群菌株占大多数。结论内蒙古地区炭疽芽胞杆菌基因SNP位点具有遗传稳定性,目前5个SNP位点可作为内蒙古地区炭疽杆菌荚膜质粒SNP位点基因分型的指标,A.Br.Ames亚群和A.Br.001/002亚群是内蒙古地区优势亚群。